Do you have questions men's health related?
Please send them!
If you have a question related to men's health, please fill the form bellow.
1. It is a must to provide a valid email, unless you want your questions to be ignored.
We won't make your email public, but we like to talk with live persons.
2. To protect
your identity, take care the name you fill. We make public your name exactly as it is.
|
Public release date: 02 October 2007
[
]
Study Supports Change to Prostate Cancer Biopsy
Adding an extra step to the standard test for prostate cancer might improve treatment for some men, a new study finds.
Doctors now use what's known as the Gleason test -- named for the physician who developed it -- as a major tool in judging
how aggressively a prostate cancer should be treated, explained lead researcher Dr. Abhijit A. Patel, a radiation
oncologist at Brigham and Women's Hospital in Boston.
His team published its findings in the Oct. 3 issue of the Journal of the American Medical Association.
In the Gleason test, doctors take a biopsy of the cancer and look at the level of disorder displayed by cells in the two
largest sections of the sample -- scoring them from 1 (less disorderly) to 5 (more disorderly).
"The less it looks like normal tissue, the more aggressive [the cancer] is," Patel explained. They then add up the two
numbers to arrive at a Gleason score. A score of 7 calls for treatment such as radiation therapy, Patel said, while
higher scores indicate an even more dangerous tumor.
In the new study, the Brigham and Women's team looked for a third pattern of disorder from another part of the samples.
Such disorderly patterns are found in about 5 percent of cases but usually are ignored. The new report included that
third pattern in the diagnostic process.
Tests on 2,370 men with prostate cancer showed that men with Gleason score 7 plus this disorderly third pattern had a
more rapid increase in prostate-specific antigen (PSA) levels in the blood. PSA indicates prostate tumor growth of the
tumor and is the basis of the common PSA diagnostic blood test.
These men should probably receive more aggressive treatment to fight their disease, Patel said, compared to men without
this combination of factors.
The time to what physicians call "PSA failure" averaged five years in these men, compared to 6.7 years in men with a
Gleason score of 7 but no disorderly third pattern. In fact, the failure time for men with a Gleason score of 7 and the
third pattern of disorderly cells was the same as for men whose cancers had a Gleason score of 8 or greater.
"We think these patients should get more therapy," Patel said. "In addition to surgery, they might need hormonal therapy
to suppress the activity of testosterone."
Testosterone, the male sex hormone, spurs the growth of prostate cancer.
It's not known yet whether more aggressive treatment for men with the disorderly third pattern will improve their outcomes,
since no such study has been done, Patel said.
But the idea does make sense, said Dr. David Berman, an assistant professor of pathology, urology and oncology at the
Johns Hopkins University School of Medicine in Baltimore. "In prostate cancer it's difficult to go with things like
survival to measure outcome. Biochemical recurrence is the easiest thing you can measure."
The revised Gleason score tested by Patel's group was first proposed several years ago, and has already been adopted by
some specialists, Berman noted.
The Hopkins expert is also the lead author of a new report, published in the October issue of Cancer Research, that
indicates that the addition of hormone suppression therapy to prostate cancer treatment might bring dangers of its own.
Laboratory studies indicate that hormone suppression therapy could boost the activity of a protein called nestin, which
promotes the movement of prostate cancer cells to other parts of the body.
That danger is far from proven, however. "These are early days to make a whole lot of therapeutic recommendations based
on it," Berman said.
More information
You can learn more about prostate cancer from the
U.S. National Cancer Institute.
|
|
